My understanding is that historically they sought the expertise with respect to commercialization by going to the private sector but not the commercial health sector. They recognized and explicitly decided not to go to pharma because of the conflicts of interest. They thought they would get the expertise with respect to pharma by talking with them.
Consult with them, have advisory committees or whatever, but don't put them on your governance table. That's the approach that has been taken historically. So this is a shift.